With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.115619-01-7,4-(4-Ethylpiperazin-1-yl)phenylamine,as a common compound, the synthetic route is as follows.
A mixture of (4-chloro-[1,3,5]triazin-2-yl)-methyl-amine (290 mg, 2.00 mmol), Nal (28 mg)and 4-(4-ethylpiperazin-1-yl)-aniline (410 mg, 2.0 mmol) in EtOH (20 ml) and N-ethyl-diisopropyl amine (350 ul, 2.0 mmol) is heated to 80C for 3 h under a nitrogen atmosphere.The reaction mixture is cooled to RT, concentrated partially in vacuo and diluted with hexaneat 0 C. The precipitate is filtered off, washed with Et2O and re-dissolved in EE and water.The separated off aqueous phase is extracted twice with EE, the organic layer washed withwater and brine, dried (Na2SO4) and concentrated, yielding the title compound: ESI-MS: 314[MH]*; TLC: Rf = 0.10 (DCM/MeOH 9:1).
115619-01-7, 115619-01-7 4-(4-Ethylpiperazin-1-yl)phenylamine 936738, apiperazines compound, is more and more widely used in various fields.
Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; IRM LLC; WO2006/420; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics